AU2008347177B2 - Compositions comprising unsaturated fatty acids and nitric oxide releasing compounds and use thereof for enhancing cognitive and related functions - Google Patents

Compositions comprising unsaturated fatty acids and nitric oxide releasing compounds and use thereof for enhancing cognitive and related functions Download PDF

Info

Publication number
AU2008347177B2
AU2008347177B2 AU2008347177A AU2008347177A AU2008347177B2 AU 2008347177 B2 AU2008347177 B2 AU 2008347177B2 AU 2008347177 A AU2008347177 A AU 2008347177A AU 2008347177 A AU2008347177 A AU 2008347177A AU 2008347177 B2 AU2008347177 B2 AU 2008347177B2
Authority
AU
Australia
Prior art keywords
animal
composition
compositions
ufa
norc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2008347177A
Other languages
English (en)
Other versions
AU2008347177A1 (en
Inventor
Yuanlong Pan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Societe des Produits Nestle SA
Original Assignee
Societe des Produits Nestle SA
Nestle SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40853324&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2008347177(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Societe des Produits Nestle SA, Nestle SA filed Critical Societe des Produits Nestle SA
Publication of AU2008347177A1 publication Critical patent/AU2008347177A1/en
Application granted granted Critical
Publication of AU2008347177B2 publication Critical patent/AU2008347177B2/en
Assigned to Société des Produits Nestlé S.A. reassignment Société des Produits Nestlé S.A. Request for Assignment Assignors: NESTEC S.A.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
    • A23D9/00—Other edible oils or fats, e.g. shortenings or cooking oils
    • A23D9/007—Other edible oils or fats, e.g. shortenings or cooking oils characterised by ingredients other than fatty acid triglycerides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/158—Fatty acids; Fats; Products containing oils or fats
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Animal Husbandry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Emergency Medicine (AREA)
  • Medical Informatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Birds (AREA)
  • Physiology (AREA)
  • Diabetes (AREA)
AU2008347177A 2008-01-04 2008-12-19 Compositions comprising unsaturated fatty acids and nitric oxide releasing compounds and use thereof for enhancing cognitive and related functions Active AU2008347177B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1009708P 2008-01-04 2008-01-04
US61/010,097 2008-01-04
US13738208P 2008-07-30 2008-07-30
US61/137,382 2008-07-30
PCT/US2008/013870 WO2009088433A1 (en) 2008-01-04 2008-12-19 Compositions comprising unsaturated fatty acids and nitric oxide releasing compounds and use thereof for enhancing congnitive and related functions

Publications (2)

Publication Number Publication Date
AU2008347177A1 AU2008347177A1 (en) 2009-07-16
AU2008347177B2 true AU2008347177B2 (en) 2014-04-17

Family

ID=40853324

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008347177A Active AU2008347177B2 (en) 2008-01-04 2008-12-19 Compositions comprising unsaturated fatty acids and nitric oxide releasing compounds and use thereof for enhancing cognitive and related functions

Country Status (11)

Country Link
US (4) US20100233304A1 (enExample)
EP (2) EP2224930B1 (enExample)
JP (1) JP5979816B2 (enExample)
CN (2) CN101909632A (enExample)
AU (1) AU2008347177B2 (enExample)
BR (1) BRPI0822238B8 (enExample)
CA (2) CA2994586C (enExample)
ES (2) ES2773928T5 (enExample)
MX (1) MX337760B (enExample)
RU (1) RU2500402C2 (enExample)
WO (1) WO2009088433A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8252742B2 (en) * 2004-12-30 2012-08-28 Hill's Pet Nutrition, Inc. Methods for enhancing the quality of life of a senior animal
JP5274248B2 (ja) 2005-05-27 2013-08-28 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 酸化窒素治療及び医生物的応用のための酸化窒素放出粒子
AU2008307494B2 (en) * 2007-10-04 2013-09-05 Société des Produits Nestlé S.A. Compositions and methods for enhancing cognitive function
AU2013200758B2 (en) * 2008-07-18 2014-06-12 Hill's Pet Nutrition, Inc. Methods for enhancing the quality of life of a senior animal
JP2011528556A (ja) * 2008-07-18 2011-11-24 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド 高齢の動物の生活の質を向上させるための方法
ES2958410T3 (es) 2009-08-21 2024-02-08 Novan Inc Geles tópicos
DK2467173T3 (da) 2009-08-21 2019-07-29 Novan Inc Sårbandager, fremgangsmåder til anvendelse heraf og fremgangsmåder til dannelse deraf
ES2593880T3 (es) * 2009-09-11 2016-12-13 Nestec, S.A. Composiciones y métodos para mejorar las funciones cognitivas y relacionadas en animales
US20130129860A1 (en) * 2009-12-29 2013-05-23 Nestec S.A. Nutritional compositions comprising fruit flakes containing docosahexaenoic acid
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
CN102552457A (zh) * 2010-12-24 2012-07-11 漆又毛 一种氨基酸和提取物组合物的药物用途
CN103442725A (zh) * 2011-01-25 2013-12-11 雀巢产品技术援助有限公司 治疗、减轻或预防动物的视觉系统衰退的方法和组合物
MX2013009544A (es) * 2011-02-18 2013-09-26 Nestec Sa Metodos y composiciones para tratar, reducir o prevenir daño al sistema nervioso de animales.
WO2012118819A2 (en) 2011-02-28 2012-09-07 Novan, Inc. Nitric oxide-releasing s-nitrosothiol-modified silica particles and methods of making the same
ES2727043T3 (es) * 2011-03-18 2019-10-11 Nestle Sa Composiciones y métodos útiles para mejorar enfermedades relacionadas con la edad
AT511776B1 (de) * 2011-07-26 2014-03-15 Gonadosan Gmbh Verwendung von citrullin und ein kombinationspräparat zur verbesserung der männlichen fertilität
US20130059028A1 (en) * 2011-09-01 2013-03-07 Julie Marie Foy Compositions and Methods for Providing a Life-Stage-Appropriate Animal Diet
CN102600124B (zh) * 2012-02-06 2014-03-26 单宝华 Omega-3增强组合物及其应用
CA2888791C (en) * 2012-10-30 2021-07-27 Kyowa Hakko Bio Co., Ltd. Use of a combination of citrulline and glutathione in the treatment of brain damage and cognitive decline
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
CN103609752B (zh) * 2013-12-02 2016-05-25 内蒙古伊利实业集团股份有限公司 一种改善脑部认知功能的组合物及其制备方法与应用
US20160341708A1 (en) * 2013-12-19 2016-11-24 Hill's Pet Nutrition, Inc. Method for determining spoilage of high protein foods
WO2015160234A1 (en) * 2014-04-17 2015-10-22 N.V. Nutricia Composition for brain improvement
EP3203857A1 (en) * 2014-10-10 2017-08-16 Nestec S.A. Compositions and methods for enhancing mobility or activity or treating frailty
MA40847A (fr) * 2014-10-22 2017-09-13 Raffaele Migliaccio Association comprenant de la spiruline et du palmitoyléthanolamide et/ou des sels ou des dérivés pharmaceutiquement acceptables de ceux-ci et leurs formulations, pour une utilisation dans la prévention et/ou le traitement d'états d'hyperactivité des tissus
AU2015372576B2 (en) * 2014-12-29 2018-09-06 Hill's Pet Nutrition, Inc. Food composition and method of use
ES2860427T3 (es) * 2015-06-22 2021-10-05 Nestle Sa Composiciones y métodos para mejorar la neurogénesis en animales
CN105602998A (zh) * 2016-01-18 2016-05-25 青岛哈拿生物科技有限公司 一种水溶性天然一氧化氮的制作方法及应用
JP2019518744A (ja) * 2016-05-27 2019-07-04 ネステク ソシエテ アノニム 運動障害を治療又は予防するための栄養組成物
EP3518919A1 (en) * 2016-09-29 2019-08-07 Société des Produits Nestlé S.A. Omega 3 fatty acids and choline as neuroprotectant in patients with no dementia
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
EP3595646A4 (en) * 2017-03-18 2021-01-13 McGarrah, Steven, M. PET FOOD WITH CANNABIDIOLIC ACID
JP7270546B2 (ja) * 2017-04-11 2023-05-10 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 個体における認知的加齢を特定及び軽減するためのオメガ３脂肪酸及びビタミンｄレベル
MA49906A (fr) 2017-08-14 2020-06-24 Axcella Health Inc Acides aminés à chaîne ramifiée pour le traitement d'une maladie du foie
EP3810123A1 (en) 2018-06-20 2021-04-28 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle
WO2022191184A1 (ja) * 2021-03-08 2022-09-15 国立大学法人九州大学 グレリン受容体感受性増強剤、グレリン受容体感受性増強用組成物及びグレリン受容体の活性化方法
EP4449875A1 (en) 2023-04-18 2024-10-23 Mars, Incorporated Composition for use for improving or preserving mental health in canine

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2268871A (en) * 1992-07-04 1994-01-26 Bio Nutritional Health Service Composition for use as a food or food supplement
US5750572A (en) * 1993-12-14 1998-05-12 Prospa B.V. Salts of a polyunsaturated fatty acid and pharmaceutical formulations containing them
US20030073747A1 (en) * 2001-10-12 2003-04-17 Gross Steven S. Reversing or preventing premature vascular senescence
US6964969B2 (en) * 2001-04-19 2005-11-15 Mccleary Edward Larry Composition and method for treating impaired or deteriorating neurological function
EP1634599A1 (en) * 2004-08-20 2006-03-15 N.V. Nutricia Iimmune stimulatory infant nutrition
EP1665940A1 (en) * 2003-09-02 2006-06-07 BBK Bio Corporation Diet food
US20060166935A1 (en) * 2005-01-24 2006-07-27 Morten Bryhn Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction
US7135498B1 (en) * 1999-06-14 2006-11-14 Henry Ford Health System Nitric oxide donors for inducing neurogenesis
US20070060651A1 (en) * 2005-08-26 2007-03-15 Nestec S.A. Compositions and methods for improving functional vascular cellular survival integrity and reducing apoptosis in ischemia

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2018A (en) * 1841-03-26 Joseph francis
US6294520B1 (en) † 1989-03-27 2001-09-25 Albert T. Naito Material for passage through the blood-brain barrier
ATE191615T1 (de) † 1995-02-23 2000-04-15 Novartis Nutrition Ag Aminosäurenzusammensetzungen und verwendung derselben klinischen nährung
CA2185983C (en) 1996-09-19 2004-04-13 Wie-Jong Kwak Process of extracting and purifying biologically effective ingredients from combined medicinal plants and their extract composition
US5874471A (en) * 1997-02-27 1999-02-23 Waugh; William Howard Orthomolecular medical use of L-citrulline for vasoprotection, relaxative smooth muscle tone and cell protection
NZ516513A (en) * 1999-06-14 2004-03-26 Ford Henry Health System Nitric oxide donors for inducing neurogenesis
JP4669095B2 (ja) 1999-07-19 2011-04-13 太陽化学株式会社 ペットの問題行動抑制組成物
US20040043013A1 (en) * 2000-12-28 2004-03-04 Mccleary Edward Larry Metabolic uncoupling therapy
US20050002992A1 (en) † 2003-06-17 2005-01-06 Mccleary Edward Larry Foods, beverages, condiments, spices and salad dressings with specialized supplements
DE60220899T2 (de) 2001-03-23 2008-03-13 Ajinomoto Co., Inc. Mittel gegen stressinduzierte krankheiten
US20060014773A1 (en) * 2001-04-19 2006-01-19 Mccleary Edward L Mental agility lozenge, edible strip, food or drink
DE10131516B4 (de) † 2001-07-02 2004-05-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Steuereinheit zur Flussregulierung
NL1019368C2 (nl) 2001-11-14 2003-05-20 Nutricia Nv Preparaat voor het verbeteren van receptorwerking.
US7514107B2 (en) * 2002-03-21 2009-04-07 Mars, Incorporated Treatment of diseases involving defective gap junctional communication
US20040001817A1 (en) † 2002-05-14 2004-01-01 Giampapa Vincent C. Anti-aging nutritional supplement
US20040087490A1 (en) * 2002-09-20 2004-05-06 Troup John P. Nutritional compositions
PL377614A1 (pl) 2003-03-18 2006-02-06 Novartis Ag Kompozycje zawierające kwasy tłuszczowe i aminokwasy
WO2005006877A1 (en) † 2003-07-03 2005-01-27 Hill's Pet Nutrition, Inc. Compositions and methods for decreasing age-related deterioration in metal activities in companion animals
US6951658B1 (en) † 2003-07-08 2005-10-04 Pearson Research & Development Limited Emu-based compositions for mental well-being and method of use
CN1898370A (zh) 2003-12-22 2007-01-17 湧永制药株式会社 油脂组合物
US20060002985A1 (en) † 2004-07-02 2006-01-05 Zicker Steven C Compositions and methods for decreasing age-related deterioration in mental activities in companion animals
AU2005322015B2 (en) † 2004-12-29 2010-02-25 Hill's Pet Nutrition, Inc. Methods for inhibiting a decline in learning and/or memory in animals
RU2362323C2 (ru) 2004-12-30 2009-07-27 Хилл`С Пет Ньютришн, Инк. Способ повышения качества жизни растущего животного и применение композиции для них
CN102907561A (zh) † 2004-12-30 2013-02-06 希尔氏宠物营养品公司 提高老年动物的生活质量的方法
CN1810257A (zh) * 2005-05-26 2006-08-02 钟健琳 活脑素口服液
WO2007004148A2 (en) 2005-06-30 2007-01-11 Koninklijke Philips Electronics N.V. Method and system for selection of information
MX336435B (es) † 2005-07-08 2016-01-19 Dsm Ip Assets Bv Acidos grasos poliinsaturados para el tratamiento de demencia y condiciones relacionadas con pre-demencia.
AU2006299665B2 (en) 2005-09-30 2012-12-13 Nestec S.A. Methods and compositions for improving cognitive function
JP5043677B2 (ja) † 2005-12-02 2012-10-10 持田製薬株式会社 アルツハイマー型認知症予防・治療剤
PL1800675T4 (pl) 2005-12-23 2012-02-29 Nutricia Nv Kompozycja zawierająca wielonienasycone kwasy tłuszczowe, białka, mangan, i/lub molibden oraz nukleozydy/nukleotydy do leczenia otępienia
KR20090003148A (ko) * 2006-04-03 2009-01-09 액세라인크 나이와 관련된 기억 손상의 치료를 위한 케톤 생성조성물의 용도
AU2008307494B2 (en) † 2007-10-04 2013-09-05 Société des Produits Nestlé S.A. Compositions and methods for enhancing cognitive function
EP2939314B1 (en) 2012-12-31 2018-08-29 Mitel Networks Corporation Interface adapter

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2268871A (en) * 1992-07-04 1994-01-26 Bio Nutritional Health Service Composition for use as a food or food supplement
US5750572A (en) * 1993-12-14 1998-05-12 Prospa B.V. Salts of a polyunsaturated fatty acid and pharmaceutical formulations containing them
US7135498B1 (en) * 1999-06-14 2006-11-14 Henry Ford Health System Nitric oxide donors for inducing neurogenesis
US6964969B2 (en) * 2001-04-19 2005-11-15 Mccleary Edward Larry Composition and method for treating impaired or deteriorating neurological function
US20030073747A1 (en) * 2001-10-12 2003-04-17 Gross Steven S. Reversing or preventing premature vascular senescence
EP1665940A1 (en) * 2003-09-02 2006-06-07 BBK Bio Corporation Diet food
EP1634599A1 (en) * 2004-08-20 2006-03-15 N.V. Nutricia Iimmune stimulatory infant nutrition
US20060166935A1 (en) * 2005-01-24 2006-07-27 Morten Bryhn Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction
US20070060651A1 (en) * 2005-08-26 2007-03-15 Nestec S.A. Compositions and methods for improving functional vascular cellular survival integrity and reducing apoptosis in ischemia

Also Published As

Publication number Publication date
EP2224930A1 (en) 2010-09-08
EP3058942B1 (en) 2019-12-04
EP3058942A1 (en) 2016-08-24
JP2011508773A (ja) 2011-03-17
CA2709660C (en) 2018-06-05
US20190030088A1 (en) 2019-01-31
BRPI0822238B1 (pt) 2020-03-10
US20210205373A1 (en) 2021-07-08
BRPI0822238B8 (pt) 2021-05-25
AU2008347177A1 (en) 2009-07-16
WO2009088433A1 (en) 2009-07-16
JP5979816B2 (ja) 2016-08-31
CA2994586C (en) 2020-07-21
RU2010132637A (ru) 2012-02-10
MX337760B (es) 2016-03-17
RU2500402C2 (ru) 2013-12-10
US20170157182A1 (en) 2017-06-08
CN101909632A (zh) 2010-12-08
US11951137B2 (en) 2024-04-09
BRPI0822238A2 (pt) 2015-06-30
CA2709660A1 (en) 2009-07-16
US10111911B2 (en) 2018-10-30
CN105267969A (zh) 2016-01-27
EP2224930A4 (en) 2011-06-22
ES2773928T3 (es) 2020-07-15
ES2773928T5 (es) 2023-06-28
US20100233304A1 (en) 2010-09-16
US10973859B2 (en) 2021-04-13
EP3058942B2 (en) 2023-03-22
CA2994586A1 (en) 2009-07-16
EP2224930B1 (en) 2016-06-15
ES2586757T3 (es) 2016-10-18

Similar Documents

Publication Publication Date Title
US11951137B2 (en) Compositions comprising unsaturated fatty acids and nitric oxide releasing compounds and use thereof for enhancing cognitive and related functions
AU2016202685B2 (en) Compositions and methods for enhancing cognitive function
CA2987033C (en) Compositions and methods for enhancing neurogenesis in animals
US20120171303A1 (en) Compositions and methods for ehnancing cognitive and related functions in animals

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ COMPOSITIONS COMPRISING UNSATURATED FATTY ACIDS AND NITRIC OXIDE RELEASING COMPOUNDS AND USE THEREOF FOR ENHANCING COGNITIVE AND RELATED FUNCTIONS

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: SOCIETE DES PRODUITS NESTLE S.A.

Free format text: FORMER OWNER(S): NESTEC S.A.